Hendrik Wessels

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2018 · 845 citations · Full text

Medicine, Hematology, Oncology +13

BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Goekbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2014 · 59 citations

Medicine, Hematology, Immunology +16

Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2015 · 53 citations

Medicine, Hematology, Oncology +16

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis

Bernhard Hemmer, Heinz Wiendl, Karsten Roth et al. · JAMA Neurology · 2023 · 34 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +17

Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial

Hendrik Wessels, Oliver von Richter, Maria Velinova et al. · Expert Opinion on Biological Therapy · 2023 · 12 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12